NZ247059A - 1-(nitrogen-substituted-sulphonyl-biphenylmethyl)-imidazole derivatives and medicaments - Google Patents

1-(nitrogen-substituted-sulphonyl-biphenylmethyl)-imidazole derivatives and medicaments

Info

Publication number
NZ247059A
NZ247059A NZ247059A NZ24705993A NZ247059A NZ 247059 A NZ247059 A NZ 247059A NZ 247059 A NZ247059 A NZ 247059A NZ 24705993 A NZ24705993 A NZ 24705993A NZ 247059 A NZ247059 A NZ 247059A
Authority
NZ
New Zealand
Prior art keywords
formula
compound
alkyl
hydrogen
mmol
Prior art date
Application number
NZ247059A
Other languages
English (en)
Inventor
Holger Heitsch
Rainer Henning
Adalbert Wagner
Hermann Gerhards
Reinhard Becker
Bernward Scholkens
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of NZ247059A publication Critical patent/NZ247059A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cephalosporin Compounds (AREA)
NZ247059A 1992-03-07 1993-03-04 1-(nitrogen-substituted-sulphonyl-biphenylmethyl)-imidazole derivatives and medicaments NZ247059A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4207241 1992-03-07

Publications (1)

Publication Number Publication Date
NZ247059A true NZ247059A (en) 1995-03-28

Family

ID=6453463

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ247059A NZ247059A (en) 1992-03-07 1993-03-04 1-(nitrogen-substituted-sulphonyl-biphenylmethyl)-imidazole derivatives and medicaments

Country Status (25)

Country Link
US (1) US5604251A (OSRAM)
EP (1) EP0560177B1 (OSRAM)
JP (1) JP3542813B2 (OSRAM)
KR (1) KR930019637A (OSRAM)
CN (1) CN1036341C (OSRAM)
AT (1) ATE230732T1 (OSRAM)
AU (1) AU663565B2 (OSRAM)
BR (1) BR9300761A (OSRAM)
CA (1) CA2091135A1 (OSRAM)
CZ (1) CZ281983B6 (OSRAM)
DE (1) DE59310323D1 (OSRAM)
DK (1) DK0560177T3 (OSRAM)
ES (1) ES2187501T3 (OSRAM)
FI (1) FI930970A7 (OSRAM)
HU (1) HUT64041A (OSRAM)
IL (1) IL104971A0 (OSRAM)
MA (1) MA22814A1 (OSRAM)
NO (1) NO303632B1 (OSRAM)
NZ (1) NZ247059A (OSRAM)
PH (1) PH31466A (OSRAM)
PL (1) PL173023B1 (OSRAM)
RU (1) RU2116300C1 (OSRAM)
SK (1) SK381192A3 (OSRAM)
TW (1) TW215434B (OSRAM)
ZA (1) ZA931585B (OSRAM)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4010797A1 (de) * 1990-04-04 1991-10-10 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
TW259786B (OSRAM) * 1992-12-17 1995-10-11 Sankyo Co
FR2716882B1 (fr) * 1994-03-04 1996-04-05 Roussel Uclaf Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques.
FR2716883B1 (fr) * 1994-03-04 1996-04-26 Roussel Uclaf Nouveaux dérivés tétrasubstitués de l'imidazole, leur préparation, nouveaux intermédiaires obtenus, leur application à titre de médicaments, compositions pharmaceutiques les renfermant.
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
JPH09124620A (ja) 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
AU717230B2 (en) 1996-02-20 2000-03-23 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
EP0944312B9 (en) * 1996-12-13 2006-07-05 ZymoGenetics, Inc. Compositions and methods for stimulating bone growth
EP0855392A3 (de) 1997-01-22 2000-01-05 Hoechst Aktiengesellschaft Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
WO1998033781A1 (en) * 1997-01-30 1998-08-06 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
JP2001520170A (ja) 1997-10-16 2001-10-30 ボード・オヴ・リージェンツ，ザ・ユニヴァーシティ・オヴ・テキサス・システム Ｎｆ−ａｔ３機能に関連した心肥大動物モデルと治療法
DE19802969A1 (de) 1998-01-27 1999-07-29 Hoechst Marion Roussel De Gmbh Verfahren zur Herstellung von S-Alkyl(Aryl)-substituierten Imidazol-Derivaten
DE19820064A1 (de) * 1998-05-06 1999-11-11 Hoechst Marion Roussel De Gmbh Substituierte Sulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
DE19832428A1 (de) * 1998-07-18 2000-01-20 Hoechst Marion Roussel De Gmbh Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19832429A1 (de) * 1998-07-18 2000-01-20 Hoechst Marion Roussel De Gmbh Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
HK1039778A1 (zh) 1999-03-19 2002-05-10 Bristol-Myers Squibb Company 制造联苯异恶唑基磺胺的方法
US20040082613A1 (en) * 2002-06-28 2004-04-29 Schneider Michael D. Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy
US20040106647A1 (en) * 2002-06-28 2004-06-03 Schneider Michael D. Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy
EP1631268A2 (en) * 2003-05-21 2006-03-08 Board Of Regents The University Of Texas System Inhibition of protein kinase c-mu (pkd) as a treatment for cardiac hypertrophy and heart failure
US8309562B2 (en) * 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
EP1660092A2 (en) * 2003-07-03 2006-05-31 Myriad Genetics, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
CA2544763A1 (en) * 2003-11-03 2005-05-12 Myogen, Inc. 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
ATE402147T1 (de) * 2003-11-03 2008-08-15 Myogen Inc 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
AU2004299058A1 (en) * 2003-12-12 2005-06-30 Aventis Pharmaceutical, Inc. Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
US20060030611A1 (en) * 2004-03-22 2006-02-09 Myogen, Inc. Enoximone sulfoxide enantiomers and their use in the treatment of PDE-III mediated diseases
WO2005092332A1 (en) * 2004-03-22 2005-10-06 Myogen, Inc. (s) - enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
WO2006007213A1 (en) * 2004-06-23 2006-01-19 Myogen, Inc. Enoximone formulations and their use in the treatment of pde-iii mediated diseases
US8258145B2 (en) * 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
EP1945242A2 (en) * 2005-07-22 2008-07-23 The Regents of the University of Colorado, A Body Corporate Inhibition of extracellular signal-regulated kinase 1/2 as a treatment for cardiac hypertrophy and heart failure
US20090306373A1 (en) * 2005-12-20 2009-12-10 Gamber Gabriel G 4,7-dihydrothieno[2,3-b]pyridine compounds and pharmaceutical compositions
CN101522222B (zh) 2006-08-01 2012-04-18 得克萨斯系统大学董事会 激活β-肌球蛋白重链表达的微RNA的鉴定
CN101883576B (zh) 2007-07-31 2015-08-19 得克萨斯系统大学董事会 调控纤维化的微小rna家族及其用途
US8202848B2 (en) 2008-03-17 2012-06-19 Board Of Regents, The University Of Texas System Identification of micro-RNAS involved in neuromuscular synapse maintenance and regeneration
WO2012064743A2 (en) 2010-11-08 2012-05-18 The Johns Hopkins University Methods for improving heart function
GB2605148A (en) * 2021-03-23 2022-09-28 Vicore Pharma Ab New compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
US4355044A (en) * 1980-12-19 1982-10-19 Bernardo Heller D-Phenylalanine treatment
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
SU1518949A1 (ru) * 1987-04-09 1995-04-30 Всесоюзный научно-исследовательский институт химии и технологии лекарственных средств Способ получения инъекционного раствора 5-этокси-2-этилтиобензимидазола
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
US5064825A (en) * 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
DE4010797A1 (de) * 1990-04-04 1991-10-10 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung
NZ238688A (en) * 1990-06-28 1992-05-26 Smithkline Beecham Corp Substituted histidines: pharmaceutical compositions, preparation and uses thereof
US5135197A (en) * 1990-08-30 1992-08-04 Qualtec Data Products, Inc. Equipment security method and apparatus
US5126342A (en) * 1990-10-01 1992-06-30 Merck & Co., Inc. Imidazole angiotensin ii antagonists incorporating acidic functional groups
US5087634A (en) * 1990-10-31 1992-02-11 G. D. Searle & Co. N-substituted imidazol-2-one compounds for treatment of circulatory disorders
CA2058198A1 (en) * 1991-01-04 1992-07-05 Adalbert Wagner Azole derivatives, process for their preparation, and their use
US5236928A (en) * 1991-03-19 1993-08-17 Merck & Co., Inc. Imidazole derivatives bearing acidic functional groups at the 5-position, their compositions and methods of use as angiotensin II antagonists
EP0599999A1 (en) * 1991-08-19 1994-06-08 E.I. Du Pont De Nemours And Company Angiotensin ii receptor blocking imidazolinone derivatives
DE4221009A1 (de) * 1992-06-26 1994-01-05 Bayer Ag Imidazolyl-substituierte Cyclohexanderivate
TW259786B (OSRAM) * 1992-12-17 1995-10-11 Sankyo Co

Also Published As

Publication number Publication date
CA2091135A1 (en) 1993-09-08
DE59310323D1 (de) 2003-02-13
BR9300761A (pt) 1993-09-14
US5604251A (en) 1997-02-18
IL104971A0 (en) 1993-07-08
NO303632B1 (no) 1998-08-10
MA22814A1 (fr) 1993-10-01
ZA931585B (en) 1993-09-27
HU9300618D0 (en) 1993-05-28
ATE230732T1 (de) 2003-01-15
HUT64041A (en) 1993-11-29
KR930019637A (ko) 1993-10-18
ES2187501T3 (es) 2003-06-16
DK0560177T3 (da) 2003-04-14
TW215434B (OSRAM) 1993-11-01
SK279109B6 (sk) 1998-06-03
FI930970A0 (fi) 1993-03-04
RU2116300C1 (ru) 1998-07-27
CN1036341C (zh) 1997-11-05
SK381192A3 (en) 1998-06-03
PL173023B1 (pl) 1998-01-30
NO930817D0 (no) 1993-03-05
AU663565B2 (en) 1995-10-12
EP0560177B1 (de) 2003-01-08
EP0560177A1 (de) 1993-09-15
CZ381192A3 (en) 1993-12-15
NO930817L (no) 1993-09-08
JPH069572A (ja) 1994-01-18
CZ281983B6 (cs) 1997-04-16
CN1076192A (zh) 1993-09-15
JP3542813B2 (ja) 2004-07-14
FI930970A7 (fi) 1993-09-08
AU3401193A (en) 1993-09-09
PL297955A1 (en) 1993-09-20
PH31466A (en) 1998-11-03

Similar Documents

Publication Publication Date Title
NZ247059A (en) 1-(nitrogen-substituted-sulphonyl-biphenylmethyl)-imidazole derivatives and medicaments
JPH07110854B2 (ja) イミダゾ−ル誘導体およびその製法
FI95254B (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten imidatsoli-fenyyli-imidatso/1,2-a/pyridiini- ja imidatsoli-fenyyli-imidatso/1,2-a/pyrimidiinijohdannaisten valmistamiseksi
RU2247121C2 (ru) 1-(п-тиенилбензил)-имидазолы в качестве агонистов рецепторов ангиотензина-(1-7) и содержащая их фармацевтическая композиция
US5444068A (en) Imidazopyridine derivatives as angiotensin II receptor antagonists, pharmaceuticals, and treatment of hypertension therewith
AU653288B2 (en) Sulphonylbenzyl-substituted pyridones
US5183899A (en) Pyrazole derivative
AU670315B2 (en) Trisubstituted biphenyls
JP2002520387A (ja) ２，５−置換されたベンゼンスルホニル尿素および−チオ尿素、それらの製法、それらの使用およびそれらを含有する医薬製剤
JPH06116244A (ja) スルホニルベンジル−置換されたイミダゾリルプロペン酸誘導体
NO792276L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-fenylamino-imidazolin-(2)-derivater
LT3373B (en) Azole derivatives, process for preparing and using thereof
MXPA01010117A (en) 1-(p-thienylbenzyl)-imidazoles as angiotensin-(1-7) receptor agonists, method for the production and the utilization thereof and pharmaceutical preparations containing said compounds